MyFinsight
Home
Blog
About
Proceeds from
convertible note
$250,000K
Proceeds from stock
option exercises
$8,755K
(1770.73%↑ Y/Y)
Proceeds from employee
stock purchase plan
$167K
(-83.51%↓ Y/Y)
Net cash provided by
financing activities
$252,770K
(16967.52%↑ Y/Y)
Canceled cashflow
$6,152K
Net increase
(decrease) in cash, cash...
$205,584K
(552.36%↑ Y/Y)
Canceled cashflow
$47,186K
Issuance costs of
convertible note
$6,152K
Accrued expenses and
other liabilities
$18,770K
(22.12%↑ Y/Y)
Stock-based compensation
$14,013K
(-42.02%↓ Y/Y)
Inventory, net
-$1,840K
(-110.76%↓ Y/Y)
Prepaid expenses and
other assets
-$1,389K
(-129.07%↓ Y/Y)
Non-cash interest on
convertible note
$555K
Amortization of debt issuance
costs
$303K
(81.44%↑ Y/Y)
Non-cash operating lease
expense
$130K
(-66.92%↓ Y/Y)
Depreciation
$5K
Proceeds from sales and
maturities of short-term...
$69,000K
(-71.04%↓ Y/Y)
Net cash used in
operating activities
-$30,272K
(83.45%↑ Y/Y)
Net cash provided by
investing activities
-$16,914K
(-112.43%↓ Y/Y)
Canceled cashflow
$37,005K
Canceled cashflow
$69,000K
Net loss
-$49,363K
(68.50%↑ Y/Y)
Purchases of short and
long-term investments
$85,874K
(-16.02%↓ Y/Y)
Accounts receivable
$7,191K
(-39.33%↓ Y/Y)
Accounts payable
-$5,969K
(-204.23%↓ Y/Y)
Other receivable
$2,436K
(40700.00%↑ Y/Y)
Collaboration receivable
(payable), net
-$1,852K
(94.13%↑ Y/Y)
Accretion of investments
$706K
(-89.63%↓ Y/Y)
Purchases of property and
equipment
$40K
Back
Back
Cash Flow
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)
source: myfinsight.com